Zeitschrift für Zytokinbiologie

Abstrakt

COVID-19 and colchicine - Can we weather the storm?

Bruno Bordallo , Mozart Bellas

We read with interest the study published by Cavalli et al. which showed that blocking interleukin-1 (IL-1) with high-dose of anakinra was safe and resulted in clinical improvement in 72% of patients with ARDS managed with non-invasive ventilation outside the intensive care unit [1]. Anakinra is a recombinant human IL-1 receptor antagonist that binds to the IL-1 receptor and block signal transduction. It is approved by FDA for rheumatoid arthritis and autoinflammatory syndromes treatment.